Catalyst Pharmaceuticals, Inc. provided earnings guidance for the year 2022. For the year, total revenues will be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues compared to 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.87 USD | -0.31% | -3.76% | -5.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.59% | 1.87B | |
-2.10% | 90.02B | |
-0.66% | 39.15B | |
-15.83% | 31.71B | |
+62.42% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-10.32% | 11.18B | |
-45.77% | 10.97B | |
+3.45% | 8.94B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022